IP Verse

(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof

EP2962690

AMGEN
Application Number
EP15177140A
Filing Date
Mar 20, 2003
Status
Granted And Under Opposition
Dec 14, 2018
Grant Date
Jan 16, 2019
External Links
Slate, Register

Biblio Summary

The patent EP2962690B1 was granted on Jan 16, 2019 by Amgen The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 15 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E. TIEFENBACHER (GMBH & CO. KG)Oct 16, 2019ADMISSIBLE
CIPLA LTDOct 16, 2019ADMISSIBLE
DR. REDDY'S LABORATORIES LIMITEDOct 16, 2019ADMISSIBLE
GALENICUM HEALTH S.L.U.Oct 16, 2019ADMISSIBLE
KRKA, D.D., NOVO MESTOOct 16, 2019ADMISSIBLE
STADAOct 16, 2019ADMISSIBLE
ZENTIVA K.S.Oct 16, 2019ADMISSIBLE
HEXAL AGOct 15, 2019ADMISSIBLE
QUIMICA SINTETICA, S.A.Oct 15, 2019ADMISSIBLE
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETIOct 15, 2019ADMISSIBLE
GENERICS UKOct 11, 2019ADMISSIBLE
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.Oct 11, 2019ADMISSIBLE
ACCORD HEALTHCARE LTDOct 10, 2019ADMISSIBLE
HOFFMANN EITLE PATENT- UND RECHTSANWALTE PARTNERSCHAFTSGESELLSCHAFT MBBOct 10, 2019ADMISSIBLE
TEVAOct 3, 2019ADMISSIBLE

More Opposed Patents of Amgen

The table below shows the patents of Amgen that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP4209499Charged Depth Filtration Of Antigen-Binding ProteinsAug 7, 20241
EP3819007Dosing Regimen For Anti-Bcma AgentsJul 10, 20244
EP2637670Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsMar 13, 20244

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents